Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-Escalation of Post-Transplant Cyclophosphamide Dosing in Older Patients
NCT05849207Phase 1Recruiting
- Start
- Oct 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide in hematologic malignancy. Primary endpoint: Maximum grade acute Graft Versus Host Disease at 100 days. Started Oct 2023; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT05849207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849207.